Whilst doing some research for the upcoming Exploratory Clinical Development World Europe conference we asked Laurence Colin, Disease Area Scientific Lead Statistician for Autoimmunity in Early Development, Novartis what challenges her organisation face in implementing new approaches for increasing productivity of drug development? Laurence's response was that there was not enough time and resources spent on clinical development plans and little quantitative assessment of competing scenarios is done. Statisticians should be involved at the early stages of clinical development planning and should make sure this quantitative assessment takes place. Also, not enough attention is paid to reducing overall sample size of early development programs, where the same question is sometimes being answered in several studies.
What are you thoughts? Do you agree?
Laurence Colin, Disease Area Scientific Lead Statistician for Autoimmunity in Early Development at Novartis will be speaking at the conference in May on, "Objective comparison of early clinical development plans and better PoC decision-making". Check out her presentation here.